Terns CEO Amy Burroughs on Cancer Drug Trial Success and Market Potential

Promising Cancer Drug Data

• 🎯 Terns Pharmaceuticals announced stunning data for its cancer drug, 701, in patients with chronic myeloid leukemia (CML) who have undergone multiple prior treatments.
• 💡 The drug achieved a 75% major molecular response rate at go-forward doses, significantly outperforming the current standard of care.
• 📈 This breakthrough offers hope for patients with difficult-to-treat CML who may be running out of options.

Path to Market and Future Trials

• 🚀 The company is aiming to move into pivotal trials by the end of 2026, with the goal of bringing the drug to patients soon after.
• 💰 A recent $750 million upsized offering will support the drug's development through pivotal data readout and market readiness.

Market Opportunity and Pipeline

• 📊 Investors are recognizing the significant market potential, with the current CML drug projected to reach $4 billion in peak sales.
• 📈 Terns 701, with its superior efficacy and potential for longer patient treatment duration, is expected to capture a meaningfully larger market share.
• 🔬 While the primary focus is on bringing Terns 701 to market, the company is an oncology-focused firm with other assets in its pipeline that will be revealed in the future.